Akari Therapeutics, Plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $19.7M
- Price
- $8.63
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.80%
- Volume
- 32.4K
About
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Quick stats
Shares outstanding2.3M
Computed float1.9M
Float / shares85.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001541157
Websitehttps://www.akaritx.com
AI Summary
AI-generated1/30
minorneutralother
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Akari Therapeutics filed PCT/US2026/45955, expanding its patent portfolio around the PH1 RNA-splicing-disrupting ADC payload.
The filing covers PH1's ability to modulate alternative splicing in pathways including angiogenesis (VEGF-A), immune-mediated cell death (FAS), and androgen receptor signaling including AR-V7 in prostate cancer.
The company's lead candidate AKTX-101 (Trop2-targeting) is in IND-enabling studies with a first-in-human trial targeted by mid-2027; AKTX-102 targets CEACAM5. The filing is a routine IP milestone with no near-term financial or clinical impact.
Red flags
- lead candidate still preclinical; first-in-human trial not until mid-2027
- company notes need for additional capital